Morgan Stanley Stoke Therapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,590,825 shares of STOK stock, worth $39.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,590,825

Previous 3,437,244 4.47%

Holding current value

$39.1 Million

Previous $37.9 Million 37.02%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$6.65 - $12.74 $1.02 Million - $1.96 Million	153,581 Added 4.47%	3,590,825 $23.9 Million
Q4 2024 Feb 14, 2025	SELL	$10.8 - $13.92 $8.3 Million - $10.7 Million	-768,063 Reduced 18.26%	3,437,244 $37.9 Million
Q3 2024 May 14, 2025	BUY	$12.24 - $15.92 $8.89 Million - $11.6 Million	726,510 Added 20.88%	4,205,307 $51.7 Million
Q3 2024 Nov 14, 2024	BUY	$12.24 - $15.92 $8.89 Million - $11.6 Million	726,510 Added 20.88%	4,205,307 $51.7 Million
Q2 2024 May 14, 2025	BUY	$11.03 - $17.52 $458,329 - $728,008	41,553 Added 1.21%	3,478,797 $47 Million
Q2 2024 Oct 17, 2024	SELL	$11.03 - $17.52 $6.02 Million - $9.57 Million	-546,205 Reduced 13.57%	3,478,797 $47 Million
Q2 2024 Aug 14, 2024	SELL	$11.03 - $17.52 $6.02 Million - $9.57 Million	-546,205 Reduced 13.57%	3,478,797 $47 Million
Q1 2024 Oct 17, 2024	BUY	$4.12 - $14.17 $2.25 Million - $7.74 Million	546,205 Added 15.7%	4,025,002 $54.3 Million
Q1 2024 Aug 16, 2024	BUY	$4.12 - $14.17 $2.7 Million - $9.28 Million	654,640 Added 19.42%	4,025,002 $54.3 Million
Q1 2024 May 15, 2024	BUY	$4.12 - $14.17 $2.7 Million - $9.28 Million	654,640 Added 19.42%	4,025,002 $54.3 Million
Q4 2023 Aug 16, 2024	SELL	$3.37 - $5.4 $365,425 - $585,549	-108,435 Reduced 3.12%	3,370,362 $17.7 Million
Q4 2023 Feb 13, 2024	BUY	$3.37 - $5.4 $1.54 Million - $2.47 Million	456,578 Added 15.67%	3,370,362 $17.7 Million
Q3 2023 Nov 15, 2023	SELL	$3.78 - $11.99 $27,563 - $87,431	-7,292 Reduced 0.25%	2,913,784 $11.5 Million
Q2 2023 Aug 14, 2023	SELL	$7.93 - $13.82 $27,374 - $47,706	-3,452 Reduced 0.12%	2,921,076 $31.1 Million
Q1 2023 May 15, 2023	BUY	$7.65 - $10.38 $3.6 Million - $4.89 Million	470,842 Added 19.19%	2,924,528 $24.4 Million
Q4 2022 Feb 14, 2023	SELL	$7.07 - $15.69 $1.12 Million - $2.48 Million	-158,356 Reduced 6.06%	2,453,686 $22.6 Million
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $48,129 - $86,334	-3,832 Reduced 0.15%	2,612,042 $33.5 Million
Q2 2022 Oct 27, 2022	BUY	$10.36 - $23.93 $660,398 - $1.53 Million	63,745 Added 2.5%	2,615,874 $34.6 Million
Q2 2022 Aug 15, 2022	BUY	$10.36 - $23.93 $660,398 - $1.53 Million	63,745 Added 2.5%	2,615,874 $34.6 Million
Q1 2022 Oct 27, 2022	SELL	$17.19 - $26.1 $1.1 Million - $1.66 Million	-63,745 Reduced 2.44%	2,552,129 $53.7 Million
Q1 2022 May 13, 2022	BUY	$17.19 - $26.1 $41.7 Million - $63.4 Million	2,428,519 Added 1964.66%	2,552,129 $53.7 Million
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $328,062 - $556,492	-18,115 Reduced 12.78%	123,610 $2.97 Million
Q3 2021 Nov 15, 2021	BUY	$23.65 - $34.44 $3.35 Million - $4.88 Million	141,725 New	141,725 $3.61 Million

Others Institutions Holding STOK

# of Institutions

134

Shares Held

60.4M

Call Options Held

5.6K

Put Options Held

142K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $429M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account